Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elderly breast cancer adjuvant chemotherapy trial comparing EC/CMF versus nab-paclitaxel + capecitabine
2008-003995-23Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Aug 2008
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of epirubicin, cyclophosphamide, capecitabine, paclitaxel, fluorouracil and 1 more in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Premature treatment discontinuation. Started Aug 2008; status: completed.
02
Drugs
epirubicincyclophosphamidecapecitabinepaclitaxelfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-003995-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003995-23.